Gesynta Pharma AB
PrivateLast Round
Series B
Jul 22, 2025
Total Funding Raised
$43.4M
Momentum
Top 50%
of companies Caplight tracks
Company Overview
Gesynta Pharma AB operates in Healthcare & Life Sciences and is based in Stockholm. Its latest recorded funding round was a Series B round in July 2025.
Gesynta Pharma AB is a clinical-stage pharmaceutical company that develops novel anti-inflammatory and pain-relieving drug candidates targeting the mPGES-1 enzyme for the treatment of chronic inflammatory diseases such as endometriosis.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Gesynta Pharma AB Comparables
Compare Gesynta Pharma AB with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Hope Medicine | 82% | |
| TiumBio Co., Ltd. | 77% | |
| FimmCyte | 77% |
For institutional investors. Book with your work email.
Gesynta Pharma AB Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jul 22, 2025 | ||||
| Series B | Jan 20, 2025 | ||||
| VC Round | Jul 7, 2020 | ||||
| VC Round | Apr 4, 2019 | ||||
| Series A | Feb 26, 2018 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Gesynta Pharma AB Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Foreground Capital | Series B |
| Innovestor | Series B |
| Catalyze Capital | Series B |
| XGEN Venture | Series B |
| Innovestor Life Science | Series B |
| HealthCap | Series B |
| Industrifonden | Series B, VC Round |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 111% MoM.
- Mar 12, 2026
Phase 2 trial started for endometriosis drug vipoglanstat.
For institutional investors. Book with your work email.
Gesynta Pharma AB Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Gesynta Pharma AB's valuation, stock price, and market status.
Is Gesynta Pharma AB a public or private company?
Gesynta Pharma AB is a private company.
What is the current stock price of Gesynta Pharma AB?
Gesynta Pharma AB is a private company, so its shares have no public market price. Caplight tracks Gesynta Pharma AB's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Gesynta Pharma AB worth (valuation)?
Valuation information for Gesynta Pharma AB is not publicly available.
Can I buy Gesynta Pharma AB stock?
Gesynta Pharma AB shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Gesynta Pharma AB's last funding round?
Gesynta Pharma AB's most recent funding round was Series B on July 22, 2025.
Who are the main investors in Gesynta Pharma AB?
Key investors in Gesynta Pharma AB include Innovestor, Innovestor Life Science, Industrifonden, Hadean Ventures.
Will Gesynta Pharma AB IPO soon?
No public IPO plans have been announced for Gesynta Pharma AB.
How can I track Gesynta Pharma AB secondary market activity?
Caplight tracks bids, offers, and trades in Gesynta Pharma AB's shares on secondary markets.